Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substances−bumetanide, nicardipine hydrochloride, and vasopressin−on the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Takeaways • Determining the return on investment (ROI) for a…
Growth is the goal in any ASC—growth in volume, growth…
The OR has a planned rhythm that relies on training,…
Free Daily News